Bio-Techne (TECH) | Stock Overview & Key Data
Bio-Techne Performance Comparison
Stock Range
Today's Range
Low: $61.87
High: $63.87
on October 3, 2025
52 Week Range
Low: $46.01
High: $80.80
on April 21, 2025
on November 6, 2024
All-Time High: $135.96 on September 20, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$9.8B
EPS
0.46
P/E Ratio (TTM)
136.85
Forward P/E
28.74
P/B Ratio
5.08
PEG Ratio
-0.96
Div. Yield
0.79%
ROE
3.68%
Beta
1.479
Debt to Equity
23.14
Financial Highlights
Profitability
Gross Margin
62.72%
Operating Margin
36.30%
Profit Margin
6.02%
Returns and Earnings
Return on Assets (TTM)
6.30%
Return on Equity (TTM)
3.68%
EBITDA
$216.9M
Net Income (TTM)
$73.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$7.87
Quarterly Revenue Growth (YoY)
3.60%
Quarterly Earnings Growth (YoY)
3.55%
Dividend Information
Last 12-Month Dividend
$0.40
Current Dividend Yield
0.79%
3-Year Average Dividend Yield
0.12%
3-Year Average Annual Dividend
$0.35
3-Year Total Dividends
$1.04
Ex-Dividend Date
August 18, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bio-Techne TECH | 9.80B Mid-cap | 21.41% | 18.02% | 18.46% | 14.75% | -11.93% | -15.82% | -14.93% | -5.01% |
| Vertex VRTX | 103.40B Large-cap | 4.55% | 1.68% | -12.25% | -16.68% | -0.61% | -11.42% | 36.61% | 49.40% |
| Regeneron REGN | 63.78B Large-cap | 6.40% | 6.42% | 9.62% | -1.74% | -16.11% | -40.76% | -16.94% | -0.34% |
| Madrigal MDGL | 9.87B Mid-cap | 4.43% | 1.78% | 48.23% | 35.44% | 41.18% | 112.57% | 490.44% | 241.88% |
| Corcept Therapeutics CORT | 8.96B Mid-cap | 5.10% | 23.56% | 21.97% | 11.06% | 76.41% | 94.03% | 232.89% | 380.38% |
| Revolution Medicines RVMD | 8.73B Mid-cap | 6.35% | 17.45% | 23.34% | 42.11% | 6.16% | -1.29% | 153.86% | 17.19% |
Ownership & Short Interest
Insider Ownership
0.26%
Institutional Ownership
103.81%
Shares Short
5M
Short Ratio
2.59
Short % of Shares Outstanding
3.87%
Average 10-Day Volume
3M
Average 90-Day Volume
3M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TECH's 52-week high and low?
- In the last 52 weeks, Bio-Techne reached a high of $80.80 (on November 6, 2024) and a low of $46.01 (on April 21, 2025).
- What is the market cap and P/E ratio for TECH?
- Curious about Bio-Techne's size and valuation? Its market capitalization stands at 9.80B. When it comes to valuation, the P/E ratio (trailing twelve months) is 136.85, and the forward P/E (looking ahead) is 28.74.
- Does TECH pay dividends? If so, what's the yield?
- Yes, Bio-Techne is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.79%, and the company has paid an average of $0.35 per share annually over the past 3 years.
- Who are Bio-Techne's main competitors or similar companies to consider before investing?
When looking at Bio-Techne, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX103.40B Healthcare Biotechnology -11.42% 36.61% Regeneron
REGN63.78B Healthcare Biotechnology -40.76% -16.94% Madrigal
MDGL9.87B Healthcare Biotechnology 112.57% 490.44% Corcept Therapeutics
CORT8.96B Healthcare Biotechnology 94.03% 232.89% Revolution Medicines
RVMD8.73B Healthcare Biotechnology -1.29% 153.86% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bio-Techne Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Bio-Techne's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 3.68%, the Debt to Equity ratio from the most recent quarter is 23.14, and its Gross Profit Margin stands at 62.72%.
- What is the recent revenue and earnings growth for TECH?
- Looking at Bio-Techne's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 3.60%, and quarterly earnings saw a YoY growth of 3.55%.
- How much of TECH stock is held by insiders and institutions?
- Wondering who owns Bio-Techne stock? Company insiders (like executives and directors) hold about 0.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 103.81%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.